Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the quinoline derivatives class. It features a diazepane ring substituted with quinoline and naphthalene moieties. The compound is listed in chemical and pharmacological databases as an experimental agent but has not been approved for any clinical use or indication. Its mechanism of action is not fully characterized; however, it has been referenced in research contexts related to integrin alpha-L (ITGAL), suggesting possible activity as an integrin ligand or modulator[10]. No clinical trials or therapeutic indications are currently associated with this molecule[2].
- Other names
- (2S)-N-methyl-2-((3S)-3-(2-methylpropyl)-2,5-dioxo-4-((quinolin-3-yl)methyl)-1,4-diazepan-1-yl)-3-(naphthalen-2-yl)propanamide(S)-2-(S)-3-isobutyl–dioxo–quinolin–methyl-[1,4]diazepan–N-methyl–naphtalen-propionamide
02
Targets
ITGAL (Integrin alpha L (CD11a))
Beyond the preview
Go deeper on (S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide.